查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1402586

纤溶治疗市场：按药物类型、按适应症、按最终用户、按给药方法、按分销管道、按患者年龄、按包装类型、按应用、按剂型、按地区

Fibrinolytic Therapy Market, By Drug Type, By Indication, By End User, By Administration (Intravenous, Intra-arterial ), By Distribution Channel, By Patient Age, By Packaging Type, By Application, By Dosage Form, By Region
出版日期: | 出版商: Coherent Market Insights | 英文 260 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球纤溶治疗市场预计将从2023年的349.6亿美元增加到2030年的450.8亿美元，2023年至2030年的年复合成长率（CAGR）为3.7%。

报告范围 报告详情
基准年 2022年 2023年市场规模 349.6亿美元
实际资料 2018-2021 预测期 2023-2030
预测期复合年增长率 3.70% 2030年市场规模预测 450.8亿美元
图 1. 2023 年按地区分類的纤溶治疗全球市场占有率(%)
纤溶治疗市场-IMG1

纤溶疗法用于溶解可能导致心臟病和中风的血栓。溶栓治疗是一种挽救生命的治疗方法，但如果存在潜在的健康问题，则可能会失败并导致其他严重的疾病和病理。溶栓治疗通常透过静脉注射进行。当一个人出现中风或心臟病发作症状并且其他治疗（例如抗凝血剂或类固醇）无效时，可以使用溶栓疗法。它可以在家中或在医院进行。组织纤维蛋白溶酶原活化剂或Alteplase是一种分解纤维蛋白和其他在体内形成血栓的物质的药物，最常用于溶栓治疗。Tenecteplase对某些患者也有效，可以口服。

市场动态

由于创伤和道路事故的增加，抗纤溶药物的需求不断增加，这推动了纤溶治疗市场的成长。这些药物越来越多地用于口腔出血治疗，主要用于治疗月经出血（月经量多），预计将进一步推动市场成长。此外，严重交通事故和创伤案件数量的增加正在创造对抗纤溶药物的需求，推动市场成长。此外，这些药物越来越多地用于治疗血友病和其他疾病，如血小板功能障碍、冯维勒布兰德病以及A型血友病和乙型血友病，进一步推动了市场的成长。

全球纤溶治疗市场也受到导致血栓的心血管、神经和肺部疾病盛行率上升的推动。根据世界卫生组织 (WHO) 统计，心血管疾病每年导致超过 1,790 万人死亡。此外，越来越多的老年人口更容易患此类疾病，也促进了市场的成长。然而，纤溶药物的高价格、严格的监管以及与治疗相关的出血风险正在阻碍市场扩张。该市场提供了开发有效重组、合成类似物和混合分子的机会，这些分子具有更高的特异性、增强的纤维蛋白特异性并降低出血风险。

然而，这些药物的高价格是阻碍市场成长的主要因素。

本研究的主要特点

  • 本报告对全球纤溶治疗市场进行了详细分析，并列出了以2022年为基准年的预测期（2023-2030）的市场规模和复合年增长率。
  • 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
  • 它根据公司亮点、产品系列、主要亮点、业绩和策略等参数，介绍了全球纤溶治疗市场的主要企业。
  • 该报告的见解使行销人员和经营团队负责人就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
  • 全球纤溶治疗市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 透过用于分析全球纤溶治疗市场的各种策略矩阵，将促进相关人员的决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
    • 司机
  • 心血管疾病发生率增加
  • 老年人口增加
  • 技术进步
  • 使用医疗保健设施
    • 压制
  • 对某些患者族群的疗效有限
  • 出血併发症的风险
  • 替代治疗方法的可用性
  • 时间敏感性和门到针延迟
    • 机会
  • 新兴市场
  • 联合治疗
  • 远端医疗和远端医疗
  • 个人化医疗
    • 主要亮点
    • 监管场景
    • 最近的趋势
    • 产品发布/核准
    • PEST分析
    • 波特的分析
    • 合併、收购和合作

第四章全球纤溶治疗市场－冠状病毒（COVID-19）大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章全球纤溶治疗市场，依药物类型，2018-2030

  • Alteplase
  • Reteplase
  • 替奈普酶
  • 链球菌激酶
  • 阿尼普酶
  • 尿激酶

第 6 章 2018-2030 年全球纤溶治疗市场（依适应症）

  • 急性缺血性脑中风
  • 急性心肌梗塞
  • 深层静脉栓塞症
  • 周围动脉血栓症
  • 其他动脉血栓症

第 7 章 全球纤溶治疗市场，依最终使用者划分，2018-2030 年

  • 医院
  • 门诊手术中心
  • 专科诊所
  • 其他的

第8章全球纤溶治疗市场，依给药方法，2018-2030

  • 静脉注射(IV)
  • 动脉内 (IA)

第9章全球纤溶治疗市场，依通路，2018-2030

  • 医院药房
  • 零售药房
  • 网路药房

第10章2018-2030年全球纤溶治疗市场（依病患年龄）

  • 成年患者
  • 儿童患者

第十一章全球纤溶治疗市场，依包装类型，2018-2030

  • 管瓶
  • 安瓿
  • 预填充式注射器

第十二章全球纤溶治疗市场，依应用分类，2018-2030

  • 紧急医疗护理
  • 介入性心臟病学
  • 血栓症形成的治疗
  • 其他的

第十三章全球纤溶治疗市场，按剂型，2018-2030

  • 用于重构的冻干粉
  • 注射液

第14章2018-2030年全球纤溶治疗市场（按地区）

  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 非洲
  • 南非
  • 中部非洲
  • 北非

第十五章竞争形势

  • 公司简介
    • Genentech, Inc.（Roche）
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Pfizer Inc.
    • Bristol Myers Squibb Company
    • Novarts AG
    • AstraZeneca PLC
    • Johnson &Johnson
    • Daiichi Sankyo Company, Limited
    • Merck &Co., Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Abbott Laboratories
    • Mallinckrodt Pharmaceuticals
    • Mitsubishi Tanabe Pharma Corporation

第16章 章节

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI5879

Global fibrinolytic therapy market is projected to reach US$ 45.08 Bn by 2030, from US$ 34.96 Bn in 2023, at a compound annual growth rate (CAGR) of 3.7% during 2023-2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 34.96 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 3.70% 2030 Value Projection: US$ 45.08 Bn
Figure 1. Global Fibrinolytic Therapy Market Share (%), By Region, 2023
Fibrinolytic Therapy Market - IMG1

Fibrinolytic therapy is used to dissolve blood clots that cause heart attacks or strokes. It is a lifesaving treatment, but it fails in underlying health problems that can lead to other serious diseases and conditions. Thrombolysis is usually given through an intravenous line. It is used when symptoms of a stroke or heart attack are present and the patient is not responding to other treatments, like anticoagulants and steroid medications. It can be given at home or in a hospital. Tissue plasminogen activator or alteplase is a drug that breaks down fibrin and other substances that create clots in the body that is most commonly used for thrombolysis. The drug tenecteplase is also effective in some patients, and it can also be given by mouth.

Market Dynamic:

The increasing incidences of trauma and road accidents are driving the demand for antifibrinolytic drugs, which in turn is fuelling fibrinolytic therapy market growth. The growing use of these drugs in oral bleeding treatments, mainly for menorrhagia (heavy menstrual flow) is again anticipated to bolster the market growth further. Moreover, rising incidences of severe road accidents and trauma is creating demand for anti-fibrinolytic drugs, thereby propelling the market growth. Furthermore, rising adoption of these drugs for treating hemophilia and other conditions such as platelet dysfunctions, Von Willebrand diseases and haemophilia A and B is further bolstering the market growth.

Also, the global fibrinolytic therapy market is driven by the rising prevalence of cardiovascular diseases, neurological disorders and pulmonary diseases causing blood clots. As per World Health Organization (WHO), cardiovascular diseases accounts for over 17.9 Mn deaths annually. Moreover, growing geriatric population prone to such diseases contributes to the market growth. However, high costs of fibrinolytic drugs, stringent regulations, and risk of bleeding associated with the therapy inhibits the market expansion. The market provides opportunities for development of effective recombinant variants, synthetic analogs, and hybrid molecules with greater specificity, enhanced fibrin specificity and reduced bleeding risks.

However, the high price of these drugs is a key factor that can hinder the market growth.

Key features of the study:

  • This report provides in-depth analysis of the global fibrinolytic therapy market, and provides market size (US$ Bn ) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global fibrinolytic therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Genentech, Inc. (Roche), Bayer AG, Boehringer Ingelheim International GmbH, Pfizer Inc., Bristol Myers Squibb Company, Novartis AG, AstraZeneca PLC, Johnson & Johnson, Daiichi Sankyo Company, Limited, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Mallinckrodt Pharmaceuticals, and Mitsubishi Tanabe Pharma Corporation
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global fibrinolytic therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibrinolytic therapy market

Detailed Segmentation:

  • Global Fibrinolytic Therapy Market, By Drug Type:
    • Alteplase
    • Reteplase
    • Tenecteplase
    • Streptokinase
    • Anistreplase
    • Urokinase
  • Global Fibrinolytic Therapy Market, By Indication:
    • Acute Ischemic Stroke
    • Acute Myocardial Infarction
    • Deep Vein Thrombosis
    • Peripheral Arterial Thrombosis
    • Other Arterial Thrombosis
  • Global Fibrinolytic Therapy Market, By End User:
    • Hospitals
    • Ambulatory Surgical Centers
    • Specialty Clinics
    • Others
  • Global Fibrinolytic Therapy Market, By Administration:
    • Intravenous (IV)
    • Intra-arterial (IA)
  • Global Fibrinolytic Therapy Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Fibrinolytic Therapy Market, By Patient Age:
    • Adult Patients
    • Pediatric Patients
  • Global Fibrinolytic Therapy Market, By Packaging Type:
    • Vials
    • Ampoules
    • Pre-filled Syringes
  • Global Fibrinolytic Therapy Market, By Application:
    • Emergency Care
    • Interventional Cardiology
    • Thrombosis Treatment
    • Others
  • Global Fibrinolytic Therapy Market, By Dosage Form:
    • Lyophilized Powder for Reconstitution
    • Solution for Injection
  • Global Fibrinolytic Therapy Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Top Companies in the Global Fibrinolytic Market:
    • Genentech, Inc. (Roche)
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Pfizer Inc.
    • Bristol Myers Squibb Company
    • Novartis AG
    • AstraZeneca PLC
    • Johnson & Johnson
    • Daiichi Sankyo Company, Limited
    • Merck & Co., Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Abbott Laboratories
    • Mallinckrodt Pharmaceuticals
    • Mitsubishi Tanabe Pharma Corporation

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Indication
    • Market Snippet, By End User
    • Market Snippet, By Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Patient Age
    • Market Snippet, By Packaging Type
    • Market Snippet, By Application
    • Market Snippet, By Dosage Form
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Driver
  • Increasing incidence of cardiovascular diseases
  • Growing geriatric population
  • Technological advancements
  • Access to healthcare facilities
    • Restrain
  • Limited efficacy in certain patient populations
  • Risk of bleeding complications
  • Availability of alternative treatment modalities
  • Time sensitivity and door-to-needle delays
    • Opportunities
  • Emerging markets
  • Combination therapies
  • Telemedicine and remote treatment
  • Personalized medicine
    • Key Highlights
    • Regulatory Scenario
    • Recent Trends
    • Product Launches/Approvals
    • PEST Analysis
    • PORTER's Analysis
    • Mergers, Acquisitions, and Collaborations

4. Global Fibrinolytic Therapy Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Fibrinolytic Therapy Market, By Drug Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Alteplase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Reteplase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Tenacteplase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Streptokinase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Anistreplase
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Urokinase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Global Fibrinolytic Therapy Market, By Indication, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Acute Ischemic Stroke
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Acute Myocardial Infarction
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Deep Vein Thrombosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Peripheral Arterial Thrombosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Other Arterial Thrombosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,US$ Bn(US$ Bn)

7. Global Fibrinolytic Therapy Market, By End User, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Speciality Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Global Fibrinolytic Therapy Market, By Administration, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Intravenous (IV)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Intra-arterial (IA)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Global Fibrinolytic Therapy Market, By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

10. Global Fibrinolytic Therapy Market, By Patient Age, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Adult Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Pediatric Patients

11. Global Fibrinolytic Therapy Market, By Packaging Types, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Vials
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Ampoules
  • Pre-filled Syringes

12. Global Fibrinolytic Therapy Market, By Application, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Emergency Care
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Interventional Cardiology
  • Thrombosis Treatment
  • Others

13. Global Fibrinolytic Therapy Market, By Dosage Form, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Lyophilized Powder for Reconstitution
  • Solution for Injection

14. Global Fibrinolytic Therapy Market , By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2018 -2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Administration, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa

15. Competitive Landscape

  • Company Profile
    • Genentech, Inc. (Roche)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Pfizer Inc.
    • Bristol Myers Squibb Company
    • Novarts AG
    • AstraZeneca PLC
    • Johnson & Johnson
    • Daiichi Sankyo Company, Limited
    • Merck & Co., Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Abbott Laboratories
    • Mallinckrodt Pharmaceuticals
    • Mitsubishi Tanabe Pharma Corporation
  • Analyst Views

16. Section

  • References
  • Research Methodology
  • About us